The CMA alleges that Alliance Healthcare bought equal volumes of nitrofurantoin from the companies to discourage competing.
News
AZ’ roxadustat successful in late-stage trial
The trial met its primary efficacy endpoint of a mean change in haemoglobin from baseline averaged over weeks 23-27.
Gilead licenses respiratory, herpes antiviral research programs from Novartis
The antivirus programs include investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses.
NICE reveals ‘health technology evaluation methods’ review
The review will cover NICE’s technology appraisals, highly specialised technologies, medical technologies, and diagnostics assessment programmes.
Promising early data for MSD’s investigational HIV drug
The company is also exploring several potential options for PrEP, including a drug-eluting implant and a once-monthly oral formulation.
Pfizer’s Rituxan biosimilar bags FDA approval
The treatment has been approved in adult patients with non-Hodgkin’s lymphoma.
First UK medical cannabis clinic launched by specialist doctors
The clinic will offer access to medicinal cannabis for all conditions acknowledged to benefit from it.
UPDATE: Animal testing hits lowest figures since 2007
New Home Office statistics show a decrease of 7% on last year, and the lowest number of procedures since 2007.
Same-day pharmacy consultations could ‘help relieve GP pressures’
The service will offer local pharmacy appointments to anyone calling NHS 111 about the minor conditions, such as earache or a sore throat.
Flow raises $1.5m for depression treatments
The treatment combines clinical psychology, neuroscience and innovative technology including machine learning.
AI used to help diagnose and treat birdshot uveitis
The Fight for Sight funded project uses AI to extract ‘hidden’ information from retinal images of patients with the rare eye condition.
New gene test could single out cancer patients eligible for ‘targeted nuclear medicine’
Testing men for faults in DNA repair genes in their tumours could identify those most likely to respond to the new type of treatment.
‘Ground-breaking’ service to help treat AF patients at risk of stroke
The Oberoi SPAF & Case Finding Service ensures high-risk AF patients receive oral anti-coagulants, helping prevent strokes.
Finalists give their thoughts on the Medical & Scientific Excellence Awards
The PharmaTimes Medical & Scientific Excellence Awards have been praised by last year’s finalists on it’s great learning and development process.
Mallinckrodt, Silence Theraputics to commercialise RNAi therapeutics
The agreement provides Mallinckrodt with an exclusive worldwide license for C3 (SLN500) – a preclinical asset that targets a specific protein in the complement pathway.
